XML 63 R50.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Expenses and Other Current Liabilities - Narrative (Details) - USD ($)
10 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2022
Research and Development Assets Acquired Other than Through Business Combination [Line Items]    
Research and development $ 35,529,331 $ 42,048,954
Phase 2 Clinical Trials    
Research and Development Assets Acquired Other than Through Business Combination [Line Items]    
Research and development   $ 4,700,000